IR Partners supports Faron Pharmaceuticals’ continuous investor communications

IR Partners serves as Faron’s long-term communications partner, providing expert, flexible, and proactive support for the company’s ongoing investor communications. Faron is an internationally listed biotechnology company traded on the London Stock Exchange’s AIM market and the Nasdaq First North Growth Market on the Helsinki Stock Exchange. Because Faron’s investor communications environment is demanding and multi-layered, it needed a partner that understands the specific characteristics of a publicly traded company’s communications and is able to support IR functions at both the strategic level and in day-to-day operations.

“The collaboration with IR Partners ensures that Faron’s investor communications remain consistent and high-quality in all situations—including during the rush of reporting periods or in changing market conditions. The partnership frees up the company’s resources and assures that communications support the strategy, build trust, and effectively reach investor audiences.” — Paavo Koivisto, Director, Investor Relations and Funding, Faron Pharmaceuticals

During the collaboration, IR Partners has, among other things, handled the planning and execution of Faron’s annual report and capital markets day, produced content for Faron’s earnings releases, and supported the company in clarifying and updating its investor story. In addition, IR Partners is closely involved in day-to-day IR work, such as drafting stock exchange releases, tailoring messages for specific channels, and resolving issues related to disclosure obligations. This ongoing collaboration ensures that the planning and execution of multi-channel investor communications are agile and that the messaging is clear and relevant to the target audience.

Kare Laukkanen

Business Director, IR and Financial Communications, Partner

+358 50 553 9535 kare.laukkanen@irpartners.fi